13-Feb-2026 12:45 PM CST - Benzinga CRISPR Therapeutics spotlights momentum for lead gene therapy as adoption widens CRISPR Therapeutics AG CRSP on Friday reported its fourth-quarter and full-year 2025 financial results, highlighting continued clinical progress, expanding uptake of Casgevy, and momentum across its gene-editing and RNA-based pipeline.
12-Feb-2026 7:12 PM CST - Yahoo Finance CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Lags Revenue Estimates CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -18.85% and -78.42%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
12-Feb-2026 2:43 PM CST - Benzinga CRISPR Therapeutics Earnings Report: Q4 Overview The earnings results for CRISPR Therapeutics (NASDAQ: CRSP) for Q4 were made public on Thursday, February 12, 2026 at 04:00 PM. Here's a comprehensive overview of the announcement. CRISPR Therapeutics missed estimated earnings by -14.17%, reporting an EPS of $-1.37 versus an estimate of $-1.2.
1-Feb-2026 2:46 AM CST - Yahoo Finance CRISPR Therapeutics Milestones And ARK Backing Contrast With Valuation Gap CRISPR Therapeutics (NasdaqGM:CRSP) has set new 2026 milestones, including planned regulatory submissions for Casgevy in patients aged 5 to 11. The company outlined progress in several clinical programs that extend beyond its first approved gene editing therapy.
13-Feb-2026 12:45 PM CST - Benzinga CRISPR Therapeutics spotlights momentum for lead gene therapy as adoption widens CRISPR Therapeutics AG CRSP on Friday reported its fourth-quarter and full-year 2025 financial results, highlighting continued clinical progress, expanding uptake of Casgevy, and momentum across its gene-editing and RNA-based pipeline.
12-Feb-2026 7:12 PM CST - Yahoo Finance CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Lags Revenue Estimates CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -18.85% and -78.42%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
12-Feb-2026 2:43 PM CST - Benzinga CRISPR Therapeutics Earnings Report: Q4 Overview The earnings results for CRISPR Therapeutics (NASDAQ: CRSP) for Q4 were made public on Thursday, February 12, 2026 at 04:00 PM. Here's a comprehensive overview of the announcement. CRISPR Therapeutics missed estimated earnings by -14.17%, reporting an EPS of $-1.37 versus an estimate of $-1.2.
1-Feb-2026 2:46 AM CST - Yahoo Finance CRISPR Therapeutics Milestones And ARK Backing Contrast With Valuation Gap CRISPR Therapeutics (NasdaqGM:CRSP) has set new 2026 milestones, including planned regulatory submissions for Casgevy in patients aged 5 to 11. The company outlined progress in several clinical programs that extend beyond its first approved gene editing therapy.
